115 related articles for article (PubMed ID: 2623384)
1. Steady-state arterial and hepatic venous plasma concentrations of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in animals--drugs which are subject to both splanchnic and extra-splanchnic elimination.
Wagner JG; Stetson PL; Knol JA; Andrews JC; Walker-Andrews S; Knutsen CA; Johnson N; Prieskorn D; Terrio P; Yang Z
Sel Cancer Ther; 1989; 5(4):193-203. PubMed ID: 2623384
[TBL] [Abstract][Full Text] [Related]
2. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL
Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990
[TBL] [Abstract][Full Text] [Related]
3. Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs.
Smith DE; Brenner DE; Knutsen CA; Deremer SJ; Terrio PA; Johnson NJ; Stetson PL; Ensminger WD
Drug Metab Dispos; 1993; 21(2):277-83. PubMed ID: 8097697
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
Stetson PL; Normolle DP; Knol JA; Johnson NJ; Yang ZM; Sakmar E; Prieskorn D; Terrio P; Knutsen CA; Ensminger WD
J Natl Cancer Inst; 1991 Nov; 83(22):1659-67. PubMed ID: 1836238
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.
Remick SC; Benson AB; Weese JL; Willson JK; Ramirez G; Wirtanen GW; Alberti DB; Nieting LM; Tutsch KD; Fischer PH
Cancer Res; 1989 Nov; 49(22):6437-42. PubMed ID: 2804987
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.
Klecker RW; Jenkins JF; Kinsella TJ; Fine RL; Strong JM; Collins JM
Clin Pharmacol Ther; 1985 Jul; 38(1):45-51. PubMed ID: 4006375
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific pharmacodynamics of 5-bromo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
Stetson PL; Maybaum J; Wagner JG; Averill DR; Wollner IS; Knol JA; Johnson NJ; Yang ZM; Preiskorn D; Smith P
Cancer Res; 1988 Dec; 48(23):6900-5. PubMed ID: 3180098
[TBL] [Abstract][Full Text] [Related]
9. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
[TBL] [Abstract][Full Text] [Related]
10. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
[TBL] [Abstract][Full Text] [Related]
11. Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients.
Robinson PJ; Bass L; Pond SM; Roberts MS; Wagner JG
J Pharmacokinet Biopharm; 1988 Jun; 16(3):229-49. PubMed ID: 3221324
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial chemotherapy for primary and metastatic liver cancers.
Ensminger W
Cancer Chemother Pharmacol; 1989; 23 Suppl():S68-73. PubMed ID: 2647314
[TBL] [Abstract][Full Text] [Related]
13. 5-Bromo-2'-deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits.
Knol JA; Stetson PL; Wagner JG; Johnson NJ; Yang ZM; Prieskorn D; Terrio P; Knutsen CA; Ensminger WD
J Surg Res; 1989 Aug; 47(2):112-6. PubMed ID: 2755115
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine into rodent DNA as determined by neutron activation analysis.
Kitchin KT; Brown JL
Anal Biochem; 1995 Aug; 229(2):180-7. PubMed ID: 7485970
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion.
Knol JA; Walker SC; Robertson JM; Yang Z; DeRemer S; Stetson PL; Ensminger WD; Lawrence TS
Cancer Res; 1995 Sep; 55(17):3687-91. PubMed ID: 7641176
[TBL] [Abstract][Full Text] [Related]
16. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Radiat Res; 1990 Aug; 123(2):192-8. PubMed ID: 2389005
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.
Russo A; Gianni L; Kinsella TJ; Klecker RW; Jenkins J; Rowland J; Glatstein E; Mitchell JB; Collins J; Myers C
Cancer Res; 1984 Apr; 44(4):1702-5. PubMed ID: 6704976
[TBL] [Abstract][Full Text] [Related]
18. Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Int J Radiat Oncol Biol Phys; 1992; 22(3):499-503. PubMed ID: 1735687
[TBL] [Abstract][Full Text] [Related]
19. Hepatic galactose elimination kinetics in the intact pig.
Keiding S; Johansen S; Winkler K
Scand J Clin Lab Invest; 1982 May; 42(3):253-9. PubMed ID: 7134810
[TBL] [Abstract][Full Text] [Related]
20. Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock.
Reinelt H; Radermacher P; Kiefer P; Fischer G; Wachter U; Vogt J; Georgieff M
Crit Care Med; 1999 Feb; 27(2):325-31. PubMed ID: 10075057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
